Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: Present status and future prospects
In Journal of Cancer Research and Therapeutics
Contributor(s): Jain V | Kalia VK | Tripathi RP | Mohanti BK | Vishwanath PN | Jalali R | Venkataramana NK | Sarin R | Banerji AK | Singh D | bsd@inmas.org | Dwarakanath BS.
Material type:
ArticleSeries: Vol 5 Issues Suppl.1.Publisher: 2009Description: S21-S26.Subject(s): 2-deoxy-D-glucose | quality of life | safety and tolerance | radiosensitization | hypofractionated radiotherapy | Glioblastoma multiforme | DDC classification: Online resources: Click here to access online
In:
Journal of Cancer Research and TherapeuticsSummary: Higher rates of glucose usage generally correlate with poor prognosis in several types of malignant tumours. Experimental studies (both in vitro and in vivo) have shown that 2-deoxy-D-glucose (2-DG), a glucose analog and glycolytic inhibitor, enhances radiation-induced damage selectively in tumor cells while protecting normal cells, thereby suggesting that 2-DG can be used as a differential radiomodifier to improve the efficacy of radiotherapy. Clinical trials undertaken to study the feasibility, safety, and validity of this suggested approach will be described. Based on 2-DG-induced radiosensitization observed in primary organ cultures of cerebral glioma tissues, clinical trials were designed taking into consideration the radiobiology of gliomas and pharmacokinetics of 2-DG. Phase I/II clinical trials have unequivocally demonstrated that a combination of 2-DG (200-300 mg 2-DG per kg body weight orally administered after overnight fasting, 20min before irradiation) with large weekly fractions (5 Gy/fraction
| Item type | Current location | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Articles
|
Tata Memorial Hospital | Available | AR9812 |
Higher rates of glucose usage generally correlate with poor prognosis in several types of malignant tumours. Experimental studies (both in vitro and in vivo) have shown that 2-deoxy-D-glucose (2-DG), a glucose analog and glycolytic inhibitor, enhances radiation-induced damage selectively in tumor cells while protecting normal cells, thereby suggesting that 2-DG can be used as a differential radiomodifier to improve the efficacy of radiotherapy. Clinical trials undertaken to study the feasibility, safety, and validity of this suggested approach will be described. Based on 2-DG-induced radiosensitization observed in primary organ cultures of cerebral glioma tissues, clinical trials were designed taking into consideration the radiobiology of gliomas and pharmacokinetics of 2-DG. Phase I/II clinical trials have unequivocally demonstrated that a combination of 2-DG (200-300 mg 2-DG per kg body weight orally administered after overnight fasting, 20min before irradiation) with large weekly fractions (5 Gy/fraction
There are no comments for this item.